baber/WOPTO huggingface dataset:
Patent EP-3570322-A2 (EP)
Title: Semiconductor package with a semiconductor chip and a passive element between a substrate and an interposer substrate electrically connected by a conductive structure
Inventor: KWON HEUNGKYU
IPC: H01L25/18
Filed: 2019-05-14
Abstract: A semiconductor package (10, 11, 12, 13, 14, 15, 16, 17) includes a substrate (100, 101, 102), a semiconductor chip (210, 220) on the substrate (100, 101, 102), a passive element (310, 311, 312) on the substrate (100, 101, 102), a conductive structure (400, 400') on the substrate (100, 101, 102) and an interposer substrate (600, 600', 600") on the semiconductor chip (210, 220), the passive element (310, 311, 312) and the conductive structure (400, 400'). The interposer substrate (600, 600', 600") may be electrically connected to the conductive structure (400, 400'). A height of the passive element (310, 311, 312) may be greater than a height of the semiconductor chip (210, 220). A lower solder connection portion (451, 451') may be provided between the substrate (100, 101, 102) and the conductive structure (400, 400') and an upper solder connection portion (452, 452') may be interposed between the conductive structure (400') and the interposer substrate (600, 600', 600"). Two semiconductor chips (210, 220) may be provided, configured to perform different functions, in particular the first semiconductor chip (210) may include one or more logic circuits and the second semiconductor chip (220) may include one or more power management integrated circuits. An upper package (20, 21) may be provided on the interposer substrate (600, 600'). An upper passive element (320) may be provided on the interposer substrate (600, 600"). The conductive structure (400') may be included in a connection structure (450), the connection structure (450) comprising also a base layer (409) of an insulating material. Alternatively, the conductive structure (400) may be included in a bonding structure (470), the bonding structure (470) also including a fixing portion (480) of a plate shape, including plastic or polymer and having penetrating holes (481) into which conductive structures (400) are inserted. At least one conductive structure (400) may be provided between the semiconductor chip (220) and passive elements (310) or between passive elements (310).
Patent EP-3762358-A2 (EP)
Inventor: HORTOBÁGYI IRÉN
IPC: C07C59/72
Filed: 2019-03-07
Abstract: The invention relates to a robust and reproducible process for the preparation of polymorph form B of treprostinil diethanolamine salt, comprising the following steps: a. treprostinil is dissolved in methanol, b. to the solution of step a) diethanolamine or its methanol solution is added, c. the reaction mixture of step b) is agitated till dissolution, d. when salt formation is completed in step c), first portion of an aprotic solvent is added to the solution, e. the solution of step d) is filtered to remove insoluble impurities, f. the filtrate of step e) is seeded with polymorph form B of treprostinil diethanolamine salt, g. to the crystal suspension obtained in step f) a second portion of the aprotic solvent is added, h. the suspension of step g) is agitated until crystallisation is completed, i. the crystals are separated, washed and dried.
Patent EP-3790614-A2 (EP)
Inventor: FRÖHLICH JOHANNES MALTA
IPC: A61M11/00
Filed: 2019-05-08
Abstract: The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one- handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.
Patent EP-3593491-A2 (EP)
Inventor: CHENG LONG
IPC: H04L9/32
Filed: 2019-02-28
Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for implementing digital certificates. One of the methods includes: generating a digital certificate; generating a digital abstract of the digital certificate; transmitting the digital abstract of the digital certificate to one or more nodes of a blockchain for storage in the blockchain; obtaining a transaction identification associated with storing the digital abstract of the digital certificate in the blockchain; and associating a digital mark with the transaction identification.
Patent EP-3899004-A2 (EP)
Inventor: GRAHAM MARK ANDREW
IPC: C07D413/04
Filed: 2019-12-17
Abstract: The present disclosure concerns the large-scale manufacture of pharmaceutical compounds, and novel intermediates for use in the manufacture. International Patent Application WO2011154737 discloses morpholine pyrimidines useful for treating cancer, processes for their preparation and pharmaceutical compositions thereof. In particular, WO2011154737 discloses, as experimental Example 2.02 on page 60, the compound 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[l-((R)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-lH- pyrrolo[2,3 -b]pyridine (hereafter referred to as the compound of Formula (I)). The structure of the compound of Formula (I) is shown below. A synthetic route to the compound of Formula (I) is described at pages 51 to 57, 66 and 67 of WO2011154737, and is summarised below in Scheme 1.
Patent EP-3819907-A2 (EP)
Inventor: LEE SANG HUN
IPC: G16H20/00
Filed: 2019-08-07
Abstract: Disclosed are a system and a method which can output, in a form that both a machine and a human can understand, a result obtained by performing a diagnosis of a disease through an image of living tissue. Provided according to an aspect of the present invention is a diagnosis result generation system comprising: a marking information generation module for generating marking information indicating a result obtained by diagnosing whether a disease is present in a slide which is a biological image, wherein the marking information includes disease state information for each pixel of the slide; a contour extraction module for extracting at least one contour from the marking information; and an XML generation module for generating an XML document including outline information of each of the extracted at least one contour.
Patent EP-3996606-A2 (EP)
Title: Dispositifs, systèmes et procédés destinés à la fixation de feuillets valvulaires cardiaques
Inventor: EGGERT JOEL T
IPC: A61B17/128
Filed: 2020-07-02
Abstract: La présente invention se rapporte d'une manière générale au domaine des dispositifs médicaux destinés à la fixation de feuillets valvulaires cardiaques. En particulier, la présente invention concerne des dispositifs, des systèmes et des procédés médicaux destinés à l'administration de cordages tendineux artificiels dans un patient. Dans un mode de réalisation, un système peut comprendre une pince dotée d'une pluralité de bras à une première extrémité. La pluralité de bras peut avoir une configuration fermée dans laquelle les bras sont orientés l'un vers l'autre, et une configuration ouverte dans laquelle les bras sont orientés à l'opposé l'un de l'autre. Une partie de ressort peut être couplée à la pluralité de bras au niveau d'une seconde extrémité qui est conçue pour solliciter les bras vers la configuration fermée. Les bras de la pince peuvent être configurés pour venir en prise de manière fixe avec un feuillet valvulaire cardiaque. La seconde extrémité de la pince peut être configurée pour s'accoupler à un cordage tendineux artificiel.
Patent EP-3924387-A2 (EP)
Inventor: EPSTEIN ALAN L
IPC: C07K14/725
Filed: 2020-02-14
Abstract: Provided herein are novel antibodies and chimeric antigen receptor (CAR) cells comprising the antigen binding domains of these antibodies. Also provided are compositions comprising the same, vector or plasmid encoding the antibodies and CARs, and methods for producing the same, or using the same for detecting or treating cancer and kits for carrying out said methods.
Patent EP-3999364-A2 (EP)
Title: Mechanical coupling device between vehicles, in particular for convoys of automatic vehicles
Inventor: ALESSANDRINI ADRIANO
IPC: B60D1/48
Filed: 2020-07-17
Abstract: A coupling device (10) of the type envisaged between a first vehicle (A) with at least two axes and a second vehicle (B) with at least two axes with the first vehicle (A) arranged to precede the second vehicle (B), in particular for the application to convoys of automatically guided vehicles, comprises a hinge coupling section (20) associated with the first vehicle (A) and a drawbar section (30) associated with the second vehicle (B), connected to each other with the possibility of rotation through the relative distal sections. The drawbar section (30) comprises an arc-shaped guide (40) arranged horizontally in front of the second vehicle (B) to extend from the right side to the left side thereof, a slider (50) sliding along the arc-shaped guide (40) and a telescopic arm (60) integral with one end of the slider (50) and rotatably connected to the other end to the coupling section (20). The coupling device (10) also advantageously a comprises steering assistance mechanism (70) suitable for a redundancy of the steering members (S) of the second vehicle (B) by setting a steering angle which is a function of the position of the slider (50) along the arc-shaped guide (40). The coupling device of the invention allows the automatic guide system to control the position and trajectories of the vehicles without any substantial exchange of forces through the device and enters into operation to allow the safe stop of the convoy when there are anomalies in the operation of the automatic guide system.
Patent EP-3931614-A2 (EP)
Inventor: THOMAS NILS
IPC: G02B23/12
Filed: 2020-02-27
Abstract: The present invention is a lightweight lens cell assembly forming a nightvision eyepiece. The lens cell has an integral focusing mechanism and at least one lens element manufactured from a polymer. Because the lens cell is manufactured from a material thermally matched to the polymer and the lens element is integrally connected to the lens cell or connected to the lens cell by an interference fit, the assembly provides significant benefits to both weight and error reduction.
Patent EP-3997111-A2 (EP)
Title: Methods for improved regeneration of transgenic plants using growth-regulating factor (grf), grf-interacting factor (gif), or chimeric grf-gif genes and proteins
Inventor: DUBCOVSKY JORGE
IPC: C07K14/415
Filed: 2020-07-08
Abstract: Disclosed are methods of producing plants with an improved regeneration efficiency using Growth-Regulating Factor ( GRF ),  GRF -Interacting Factor ( GIF ), or chimeric  GRF - GIF  genes and proteins. The disclosure also provides plants with an improved regeneration efficiency that are produced by the disclosed methods, methods of reducing the use of exogenous cytokinins in the regeneration of plants, and methods of improving the regeneration efficiency of plants.
Patent EP-4061128-A2 (EP)
Title: Placental tissue particulate compositions and methods of use
Inventor: PAVESIO ALESSANDRA
IPC: A61F2/02
Filed: 2020-11-13
Abstract: Provided herein are compositions containing dehydrated placental tissue particulates, methods of making the compositions and methods for treating various musculoskeletal disorders and other conditions using such compositions, including osteoarthritis (OA), degenerative disc disease, tendonitis, plantar fasciitis, and pain associated therewith.
Patent EP-3972084-A2 (EP)
Title: Systems and methods for monitoring energy-related data in an electrical system
Inventor: BICKEL JON A
IPC: H02J3/14
Filed: 2021-09-02
Abstract: A method for monitoring energy-related data in an electrical system includes processing energy-related data from or derived from energy-related signals captured by at least one intelligent electronic device in the electrical system to identify at least one variation/change in the energy-related signals. The method also includes determining if the at least one identified variation/change meets a prescribed threshold or thresholds, and in response to the at least one identified variation/change meeting the prescribed threshold or thresholds, characterizing and/or quantifying the at least one identified variation/change. Information related to the characterized and/or quantified at least one identified variation/change is appended to time-series information associated with the energy-related data, and characteristics and/or quantities associated with the time-series information are evaluated to identify at least one potential load type associated with the characterized and/or quantified at least one identified variation/change.
Patent EP-3996224-A2 (EP)
Inventor: PAL MAYUKHA
IPC: H02H1/00
Filed: 2021-09-22
Abstract: The present invention discloses a system (200) and method for nuisance-trip decision management in an electric power system using data analytics comprising, a protection system, PS, (202), and at least one electrical protection circuit, EPC, (204). The PS (202) comprising, a plurality of sensors (206) configured to measure data ; a memory (208) configured to store an updated data of nuisance-trip events and a plurality of nuisance-trip parameters detected or generated on the electric power system over a period; a processor (210) configured to perform hybrid machine learning (HML) based on the measured data from the plurality of sensors for a nuisance-trip condition and communicate with a neighboring PS (220a, 220b,220c); a protection microcontroller (212) configured to allow or avoid tripping at least one electronic tripping circuit (214) provided in the at least one EPC by communicating with the processor (210) and the neighboring PS (220a, 220b,220c).
Patent EP-4172204-A2 (EP)
Inventor: FILARSKY KATHARINA
IPC: A61P35/00
Filed: 2021-06-25
Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.
Patent EP-4243049-A2 (EP)
Title: Movable contact part and direct current relay comprising same
Inventor: YOO JUNG WOO
IPC: H01H50/36
Filed: 2021-11-02
Abstract: Disclosed are a movable contact part and a direct current relay comprising the same. The movable contact part, according to one embodiment of the present invention, comprises a coupling part which is provided to each component. The coupling part provided to each component is coupled to the coupling part provided to another adjacently positioned component.Thus, a coupled state between each of the components constituting the movable contact part may be easily and stably formed.
Patent EP-4244341-A2 (EP)
Title: Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
Inventor: TSAIOUN KATYA
IPC: C12N9/12
Filed: 2021-11-12
Abstract: Provided herein are MK2 activators, and compositions comprising an MK2 activator, for the treatment of a vascular disorder or an endothelial barrier disorder in a patient in need thereof, whereby the MK2 activator has a molecular weight below 1000 Da and binds to a binding pocket located on the C-lobe domain and C -terminal Regulatory Domain of MK2. Also provided are methods of treating a vascular disorder or an endothelial barrier disorder in a patient by administering to the patient an MK2 activator.
Patent EP-4060286-A2 (EP)
Inventor: SASAKI TAKESHI
IPC: E02F9/26
Filed: 2022-03-18
Abstract: A surveying system (1) includes an information processing device (100) and a surveying device (420) and further includes a scanner unit (260) configured to perform a measurement to acquire three-dimensional point cloud data on the surveying device (420), a measurement position specifying unit (127) configured to specify a measurement position for which three-dimensional point cloud data needs to be acquired, a position acquisition unit (270) configured to acquire a self-position of the surveying device (420), and a measurement computing unit (223) configured to perform a computation to measure the measurement position from the self-position.
Patent EP-4116269-A2 (EP)
Title: Additive manufacture of optical components
Inventor: SOUTHARD BARI M
IPC: C03C23/00
Filed: 2017-11-09
Abstract: A method of forming an optical component includes depositing slurry that includes glass powder material onto a facesheet (104) and fusing the glass powder material to a facesheet to form a first core material layer (106) on the facesheet. The method also includes successively fusing glass powder material in a plurality of additional core material layers (108) to build a core material structure on the facesheet. The method can include selectively depositing slurry including glass powder material over only a portion of at least one of the facesheet, the first core material layer, and/or the one of the additional core material layers. Depositing the slurry can include extruding the slurry from an extruder.
Patent EP-4219997-A2 (EP)
Title: Fluid connector with face seal
Inventor: BENCKE JAMES MCKENSEY
IPC: F16L37/086
Filed: 2016-03-08
Abstract: One form of the present technology includes a fluid connector for delivery of breathing gas to a patient from a respiratory pressure therapy device, the fluid connector including a first end with a first opening to deliver a fluid flow, a seal portion extending around a periphery of the first opening, and a latching portion, a second end with a second opening to receive the fluid flow, a sealing surface extending around a periphery of the second opening and configured to engage the seal portion to form a face seal, and a complementary latching portion configured to engage with the latching portion
Patent EP-4249104-A2 (EP)
Inventor: WILKINSON WILLIAM R
IPC: B01D53/047
Filed: 2013-10-14
Abstract: Described herein are various embodiments of an oxygen concentrator system. In some embodiments, oxygen concentrator system includes one or more components that improve energy usage during operation of the oxygen concentrator system.
Patent EP-4234576-A2 (EP)
Inventor: LU YONG-CHEN
IPC: C07K14/705
Filed: 2018-03-28
Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.
Patent EP-4255022-A2 (EP)
Title: Master node, secondary node, user equipment, and methods performed in a communication network
Inventor: DA SILVA ICARO LEONARDO
IPC: H04W36/00
Filed: 2021-03-02
Abstract: Embodiments herein relate to e.g. a method performed by a user equipment, UE, (10) for handling cell change of a secondary cell for the UE (10). The UE receives from a master node (12), a message of a first RAT comprising a reconfiguration message for a conditional reconfiguration of the secondary cell of a second RAT. The UE transmits to the master node, a first complete message of the second RAT embedded in another message of the first RAT, wherein the first complete message indicates that the UE is able to comply to the conditional reconfiguration. The UE (10) further transmits to the master node (12), upon fulfilment of a condition of the conditional reconfiguration, a second complete message of the second RAT embedded in a RRC message of the first RAT.
Patent EP-4270888-A2 (EP)
Inventor: LIU YONG
IPC: H04L27/26
Filed: 2019-05-06
Abstract: This application provides a communication method and a communications apparatus. The method includes: determining, by a terminal device, power of a DMRS; and sending, by the terminal device, the DMRS based on the determined power. In embodiments of this application, the power of the DMRS can be flexibly determined for different communication statuses.
Patent EP-4241647-A2 (EP)
Inventor: DICKRELL MARTIN L
IPC: A47L11/40
Filed: 2016-12-09
Abstract: A surface maintenance machine comprising two front wheels, at least one rear wheel, a motive source for providing motive force to at least one front wheel to drive the machine on a surface. Embodiments also include an operator platform allowing an operator to stand thereon extending at least partly around the rear wheel, for supporting an operator in a standing position with the operator's feet on either side of the rear wheel.
Patent EP-4269618-A2 (EP)
Inventor: SHENDURE JAY
IPC: C12Q1/6869
Filed: 2019-06-04
Abstract: Provided herein are methods for preparing a sequencing library that includes nucleic acids from a plurality of single cells. In one embodiment, the sequencing library includes nucleic acids that represent the whole transcriptomes from the plurality of single cells. In one embodiment, the nucleic acids include three index sequences. Also provided herein are compositions, such as compositions that include the nucleic acids having three index sequences